Deferiprone

[1]Kontoghiorghes GJ, et al. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. 2003;26 (8) :553-584.|[2]Rui V. Simões, Inhibition of prostate cancer proliferation by Deferiprone. NMR Biomed|[3]Oded Shalev. et al. Deferiprone (L1) Chelates Pathologic Iron Deposits From Membranes of Intact Thalassemic and Sickle Red Blood Cells Both In Vitro and In Vivo.|[4]Ngan Thi Tran, et al. Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition. Platelets 2020 May 18;31 (4) :505-512. |[5]Andrea Pagani, MD, et al. Deferiprone Stimulates Aged Dermal Fibroblasts via HIF-1α Modulation.Pathog Dis. 2018 Jul 1;76 (5) .|[6]Débora C Coraça-Huber, et al. Iron chelation destabilizes bacterial biofilms and potentiates the antimicrobial activity of antibiotics against coagulase-negative Staphylococci. Pathogens and Disease, Volume 76, Issue 5, July 2018, fty052|[7]Shalini S. Rao, et al. Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology. Neurotherapeutics. 2021 Apr;18 (2) :1081-1094.|[8]Makhdoumi P, et al. Oral deferiprone administration ameliorates cisplatin-induced nephrotoxicity in rats.J Pharm Pharmacol. 2018 Oct;70 (10) :1357-1368. |[9]Yanan Zhang, et al. Taurine and deferiprone against Al-linked apoptosis in rat hippocampus. J Trace Elem Med Biol. 2023 Mar;76:127113.